drugset / Trial / NCT05582837

Treatment of Meniere's Disease With Migraine Medications

NCT05582837

Phase 4 Recruiting 40 enrolled University of California, Irvine
RandomizedParallel-groupTriple-blindTreatment

Summary

Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.

Timeline

Start
2022-08-01
Primary completion
2027-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nortriptyline Small molecule 7.5 mg
Subject Topiramate Small molecule 10 mg

Indications